Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sequent Scientific Limited ( (IN:SEQUENT) ) just unveiled an announcement.
Viyash Scientific Limited has notified stock exchanges that following the court-approved composite scheme of amalgamation under which Symed Labs merged into Viyash Lifesciences and subsequently into Viyash Scientific, Symed has ceased to exist as a separate entity, leading Crisil to withdraw the credit ratings previously assigned to Symed’s bank facilities in line with its withdrawal policy. The move consolidates Symed’s API operations within the Viyash/Sequent structure, simplifying the group’s financing profile while reinforcing the Carlyle-backed company’s position as a global pharmaceutical and animal health player with improving financial metrics, including rising revenue, healthy profitability and very low leverage, which are likely to be viewed positively by lenders and investors.
More about Sequent Scientific Limited
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is a Carlyle-backed pharmaceuticals group with a strong presence in animal health APIs and formulations, supported by seven manufacturing facilities, five R&D centres, and distribution in over 100 countries. Through its subsidiary Viyash Lifesciences, the group also operates as a mid-tier active pharmaceutical ingredient and formulations player, with multiple USFDA-approved facilities catering to both regulated and semi-regulated global markets; Symed Labs, now amalgamated into the group, historically manufactured about 50 APIs for overseas markets from four USFDA-approved plants near Hyderabad.
Average Trading Volume: 90,663
Technical Sentiment Signal: Buy
Current Market Cap: 49.11B INR
For an in-depth examination of SEQUENT stock, go to TipRanks’ Overview page.